Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC

Fertilys

Status: Withdrawn

Conditions: Infertility, Female

Treatments: Procedure: Intrauterine administration of hCG-activated peripheral blood mononuclear cells

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04753736

Immunophenotypage RIF and RM

Details and patient eligibility

About

The purpose of this study is to identify a systemic immunological profile specific to patients with recurrent implantation failures (RIF) or miscarriages (RM) through blood immunophenotyping on the day of ovulation. This study also aims to determine whether the intrauterine administration of 5 million peripheral blood monocluear cells increases implantation and pregnancy rates in patients with RIF and decreases the risk of miscarriages in patients with RM, compared to what has already been published in the scientific literature

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All women aged 18 and over undergoing an IVF cycle with her partner's sperm at the Fertilys fertility center, without a RIF status, agreeing to participate in the study and having signed the consent form to participate in the study.
• All women aged 18 and over undergoing an IVF cycle with her partner's sperm at the Fertilys fertility center, with a RIF or RM status, agreeing to participate in the study and having signed the consent form to participate in the study.

Exclusion criteria

• Women who need a gametes donor (eggs and / or sperm).
• Women undergoing an IVF cycle with frozen sperm.
• Women with autoimmune disease.
• Women with diabetes.
• Women with a history of chemotherapy treatment.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 3 patient groups

No recurrent implantation failure

No Intervention group

Recurrent implantation failures

Experimental group

Treatment:

Procedure: Intrauterine administration of hCG-activated peripheral blood mononuclear cells

Recurrent miscarriage

Experimental group

Treatment:

Procedure: Intrauterine administration of hCG-activated peripheral blood mononuclear cells